In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J. Craig Venter Institute

www.tigr.org

Latest From J. Craig Venter Institute

Life Science Start-Ups: Venture Funding, April 2014

Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced February through March 2014.

BioPharmaceutical Medical Device

Craig Venter Wants To Extend Your Life (And Own Your Data)

The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.

BioPharmaceutical Personalized Medicine

Venter Targets Life Extension With New Genomic Research Company

The former Celera CEO has raised $70 million for a new organization that will use genomic, biochemical and microbiome data to find stem cell-based treatments for aging-related disorders.

BioPharmaceutical Medical Device

Advancis Pharmaceutical Corp.

Advancis Pharmaceutical Corp. is tackling antibiotic resistance with pulsed dosing technology that delivers repetitive bursts of anti-infective medications--both existing drugs and NCEs--in an attack pattern that denies microorganisms the chance to regroup between doses. This approach promises to work with lower total dosages and shorter durations of therapy, reducing side effects and aiding patient compliance.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • The Institute for Genomic Research
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Tech. Transfer Entity
  • Parent & Subsidiaries
  • J. Craig Venter Institute
  • Senior Management
  • J. C Venter, PhD, Chmn., Pres. & CEO
    Aimee Turner, CFO
    Claire Fraser, PhD, Dir., R&D
  • Contact Info
  • J. Craig Venter Institute
    Phone: (301) 838-0200
    9712 Medical Center Dr.
    Rockville, MD 20850
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register